Permanens Capital L.P. bought a new position in Humana Inc. (NYSE:HUM - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 3,884 shares of the insurance provider's stock, valued at approximately $1,546,000.
Several other institutional investors and hedge funds have also recently bought and sold shares of HUM. Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in shares of Humana by 4.1% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 250,330 shares of the insurance provider's stock valued at $66,207,000 after buying an additional 9,960 shares in the last quarter. Manning & Napier Advisors LLC purchased a new position in Humana in the 2nd quarter worth approximately $1,412,000. Sustainable Insight Capital Management LLC grew its position in Humana by 23.7% in the fourth quarter. Sustainable Insight Capital Management LLC now owns 24,757 shares of the insurance provider's stock valued at $6,341,000 after acquiring an additional 4,740 shares in the last quarter. Pzena Investment Management LLC acquired a new stake in Humana in the second quarter valued at approximately $1,749,014,000. Finally, Swedbank AB raised its stake in shares of Humana by 6.2% during the fourth quarter. Swedbank AB now owns 111,803 shares of the insurance provider's stock valued at $28,636,000 after purchasing an additional 6,534 shares during the period. Institutional investors and hedge funds own 92.38% of the company's stock.
Analyst Upgrades and Downgrades
Several research analysts have recently weighed in on HUM shares. Robert W. Baird set a $390.00 target price on shares of Humana in a research note on Thursday, July 30th. Needham & Company LLC started coverage on shares of Humana in a research note on Wednesday, May 20th. They set a "buy" rating on the stock. Seaport Research Partners lowered shares of Humana to a "neutral" rating in a report on Wednesday, May 20th. TD Cowen upped their price objective on shares of Humana from $350.00 to $370.00 and gave the company a "hold" rating in a research report on Friday, July 31st. Finally, Mizuho raised their target price on Humana from $335.00 to $390.00 and gave the company an "outperform" rating in a research note on Monday, June 8th. Fourteen research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $403.91.
Read Our Latest Research Report on HUM
Humana Stock Up 0.1%
Shares of NYSE:HUM opened at $390.06 on Thursday. The firm has a market cap of $46.84 billion, a PE ratio of 36.90, a price-to-earnings-growth ratio of 2.22 and a beta of 0.72. The company has a fifty day simple moving average of $384.44 and a 200 day simple moving average of $286.38. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.62. Humana Inc. has a 12-month low of $163.11 and a 12-month high of $428.88.
Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings data on Wednesday, July 29th. The insurance provider reported $7.61 EPS for the quarter, beating analysts' consensus estimates of $7.27 by $0.34. The firm had revenue of $40.89 billion for the quarter, compared to the consensus estimate of $40.58 billion. Humana had a net margin of 0.88% and a return on equity of 11.20%. The firm's revenue was up 26.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $6.27 EPS. On average, equities research analysts anticipate that Humana Inc. will post 9.12 EPS for the current fiscal year.
Humana Profile
(
Free Report)
Humana Inc NYSE: HUM is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana's products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.
In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.
Further Reading
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Humana, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.
While Humana currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
